NFL Biosciences shares fall to €0.34 support, RSI at 27
The Montpellier-based biotech's shares are losing ground mid-session, just as the company has announced a patent filing. The decline is part of a downward trend that has lasted several months.
Price below all moving averages, RSI in oversold territory
The shares of NFL Biosciences fell 7.2% to €0.3480 from €0.375 the previous day, approaching support at €0.3415. The price is below its 20-period moving average (a gap of 20.91%), and the RSI at 27 reflects selling exhaustion after a series of difficult sessions.
The decline is more pronounced over the longer term: the stock has dropped 59.49% over three months, but has gained 1.9% over seven days. The CAC 40 is barely moving, at 8,363 points (+0.02%), which isolates the move in the stock.
Patent filed on November 13 to protect NFL-102 until 2047
NFL Biosciences announced on November 13 the filing of a patent application aimed at strengthening the protection of its drug candidate against tobacco dependence and extending it to new therapeutic applications. If a patent is granted on this basis, NFL-102 could be protected until 2047, excluding possible regulatory extensions.
On October 22, the company obtained authorization from the ANSM and the Committee for the Protection of Persons for the phase 2 TONIC trial, with first enrollments planned for November and first results expected in April 2027. The next milestone is the publication of the results of this first part of the study.
